Evidence map›Paper›PMID 27567954›Full record

ArticleTranslational oncology2016

Global Conservation of Protein Status between Cell Lines and Xenografts.

Julian Biau, Emmanuel Chautard, Frank Court, Bruno Pereira, Pierre Verrelle, Flavien Devun, Leanne De Koning, Marie Dutreix

Open access · goldAbstract read
In one paragraph

Article in Translational oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Pancreatic Cancer and Platelets Crosstalk: A Potential Biomarker and Target.Frontiers in cell and developmental biology · 2021
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

Julian BiauInstitut Curie, Centre de Recherche, 91400 Orsay/75248 Paris, France; UMR3347, Centre National de la Recherche Scientifique, 91400 Orsay, France; U1021, Institut National de la Santé et de la Recherche Médicale, 91400 Orsay, France; Université Paris Sud, 91400 Orsay, France; Clermont Auvergne University, EA7283 CREaT, 63011 Clermont-Ferrand, France; Radiotherapy Department, Centre Jean Perrin, 63011 Clermont-Ferrand, France. Electronic address: Julian.biau@clermont.unicancer.fr.
Emmanuel ChautardClermont Auvergne University, EA7283 CREaT, 63011 Clermont-Ferrand, France; Radiotherapy Department, Centre Jean Perrin, 63011 Clermont-Ferrand, France.
Frank CourtU1103, Institut National de la Santé et de la Recherche Médicale, 63001 Clermont-Ferrand, France; UMR 6293, Centre National de la Recherche Scientifique, 63001 Clermont-Ferrand, France; Clermont Auvergne University, GReD Laboratory, Clermont-Ferrand, 63000, France.
Bruno PereiraBiostatistics Department, DRCI, Clermont-Ferrand Hospital, Clermont-Ferrand, 63003, France.
Pierre VerrelleInstitut Curie, Centre de Recherche, 91400 Orsay/75248 Paris, France; UMR3347, Centre National de la Recherche Scientifique, 91400 Orsay, France; U1021, Institut National de la Santé et de la Recherche Médicale, 91400 Orsay, France; Clermont Auvergne University, EA7283 CREaT, 63011 Clermont-Ferrand, France; Radiotherapy Department, Institut Curie, 75005 Paris, France.
Flavien DevunInstitut Curie, Centre de Recherche, 91400 Orsay/75248 Paris, France; DNA Therapeutics, Evry, Paris, France.
Leanne De KoningInstitut Curie, Department of Translational Research, RPPA platform,75248 Paris cedex05, France.
Marie DutreixInstitut Curie, Centre de Recherche, 91400 Orsay/75248 Paris, France; UMR3347, Centre National de la Recherche Scientifique, 91400 Orsay, France; U1021, Institut National de la Santé et de la Recherche Médicale, 91400 Orsay, France; Université Paris Sud, 91400 Orsay, France.
Centre Jean Perrin · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRCentre National de la Recherche Scientifique · FRHiFiBiO Therapeutics (France) · FRInstitut Curie · FRInstitut d'Imagerie Biomédicale · FRUniversité Clermont Auvergne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Common preclinical models for testing anticancer treatment include cultured human tumor cell lines in monolayer, and xenografts derived from these cell lines in immunodeficient mice. Our goal was to determine how similar the xenografts are compared with their original cell line and to determine whether it is possible to predict the stability of a xenograft model beforehand. We studied a selection of 89 protein markers of interest in 14 human cell cultures and respective subcutaneous xenografts using the reverse-phase protein array technology. We specifically focused on proteins and posttranslational modifications involved in DNA repair, PI3K pathway, apoptosis, tyrosine kinase signaling, stress, cell cycle, MAPK/ERK signaling, SAPK/JNK signaling, NFκB signaling, and adhesion/cytoskeleton. Using hierarchical clustering, most cell culture-xenograft pairs cluster together, suggesting a global conservation of protein signature. Particularly, Akt, NFkB, EGFR, and Vimentin showed very stable protein expression and phosphorylation levels highlighting that 4 of 10 pathways were highly correlated whatever the model. Other proteins were heterogeneously conserved depending on the cell line. Finally, cell line models with low Akt pathway activation and low levels of Vimentin gave rise to more reliable xenograft models. These results may be useful for the extrapolation of cell culture experiments to in vivo models in novel targeted drug discovery.

Identifiers

PMID27567954
PMCPMC5006813
OpenAlexW2518124527

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.